Last reviewed · How we verify

NCT06562231

Development of Isthmocele Symptom Severity and Quality of Life Scale

Recruiting now Last updated 20 August 2024
What this trial tests

trial testing quality of life scale in Quality of Life in 330 participants. Currently enrolling.

Timeline
1 January 2023
Primary endpoint
1 June 2025
30 December 2025

Quick facts

Lead sponsorHilal Yuvacı
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment330
Start date1 January 2023
Primary completion1 June 2025
Estimated completion30 December 2025
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Hilal Yuvacı

Who can join

Adults 18 to 45, female only, with Quality of Life. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Isthmocele, also known as cesarean scar defect (CSD), is the disruption of the integrity of the myometrium in the cesarean section incision and the indentation of the opening in the myometrium towards the visceral peritoneum. Residual menstrual blood accumulating in the isthmocele sac can cause chronic endometritis, anormal uterine bleeding, infertility and chronic pelvic pain. There is currently no quality of life scale that assesses isthmocele symptoms. A scale is needed to determine the positive effect on the patient's quality of life after the surgeries are performed. This study it is aimed to develop a scale that evaluates the severity of isthmocele symptoms and the impact on quality of life due to isthmocele.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Quality of Life

Currently open trials in the same condition.

Other Hilal Yuvacı trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06562231.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing